Paltusotine May Address Unmet Need in NETs Patients With Carcinoid Syndrome
Paltusotine can alleviate symptoms of carcinoid syndrome in patients with neuroendocrine tumors, a phase 2 study suggests.
Related Articles
Data for NVL-655 in Advanced ALK+ NSCLC and Solid Tumors from the ALKOVE-1 Trial
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Program
Program details for the 13th AACR-JCA Joint Conference: From Cancer Discovery Science to Therapeutic Innovation
Dual Inhibition of SYK and EGFR Overcomes Chemoresistance by Inhibiting CDC6 and Blocking DNA Replication
SYK and EGFR coinhibition exerts synergistic anticancer effects in chemoresistant ovarian cancer, providing a strategy to treat chemotherapy-resistant ovarian cancers using clinically available agents by…
Marching through a testicular cancer diagnosis
Grayson Niemi juggled chemo treatments for testicular cancer and practice sessions for joining Ohio State’s marching band. He made the band and also to the…
Lung Cancer Screening
Together, Fred Hutchinson Cancer Center and UW Medicine offer screening for people at high risk for lung cancer.
ASTCT Learning Center: International Survivorship Guidelines Surveillance Recs on SMN Screening
The webinar will focus on international survivorship guidelines surveillance recs on SMN screening- specifically breast and colorectal cancer and will provide more background and rationale…
Exploring the Evolving Role of CAR T-Cell Therapies in Multiple Myeloma
Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.
Eflornithine Improves Survival in Brain Cancer
Treatment with eflornithine led to clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) for patients with recurrent grade 3 IDH-mutant astrocytoma, an…
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
Since European LeukemiaNet (ELN) acute myeloid leukemia (AML) genetic risk classification systems are based on patients treated with intensive chemotherapy
